Elsevier eBooks, Journal Year: 2023, Volume and Issue: unknown, P. 141 - 153.e1
Published: May 11, 2023
Language: Английский
Journal of clinical lipidology, Journal Year: 2024, Volume and Issue: 18(3), P. e320 - e350
Published: April 24, 2024
BACKGROUNDThis joint expert review by the Obesity Medicine Association (OMA) and National Lipid (NLA) provides clinicians an overview of pathophysiologic clinical considerations regarding obesity, dyslipidemia, cardiovascular disease (CVD) risk.METHODSThis is based upon scientific evidence, perspectives authors, peer OMA NLA leadership.RESULTSAmong individuals with adipose tissue may store over 50% total body free cholesterol. Triglycerides represent up to 99% lipid species in tissue. The potential for expansion accounts greatest weight variance among most individuals, percent fat ranging from less than 5% 60%. While population studies suggest a modest increase blood low-density lipoprotein cholesterol (LDL-C) levels excess adiposity, adiposopathic dyslipidemia pattern often described adiposity includes elevated triglycerides, reduced high density (HDL-C), increased non-HDL-C, apolipoprotein B, LDL particle concentration, small, dense particles.CONCLUSIONSObesity increases CVD risk, at least partially due promotion adiposopathic, atherogenic profile. also worsens other cardiometabolic risk factors. Among patients interventions that reduce improve outcomes are generally associated improved levels. Given improvement LDL-C reduction overweight or early treat both (LDL-C and/or non-HDL-C) priorities reducing CVD. This risk. leadership. particles.
Language: Английский
Citations
27
Obesity Pillars, Journal Year: 2024, Volume and Issue: 10, P. 100108 - 100108
Published: March 12, 2024
This joint expert review by the Obesity Medicine Association (OMA) and National Lipid (NLA) provides clinicians an overview of pathophysiologic clinical considerations regarding obesity, dyslipidemia, cardiovascular disease (CVD) risk. is based upon scientific evidence, perspectives authors, peer OMA NLA leadership. Among individuals with adipose tissue may store over 50% total body free cholesterol. Triglycerides represent up to 99% lipid species in tissue. The potential for expansion accounts greatest weight variance among most individuals, percent fat ranging from less than 5% 60%. While population studies suggest a modest increase blood low-density lipoprotein cholesterol (LDL-C) levels excess adiposity, adiposopathic dyslipidemia pattern often described adiposity includes elevated triglycerides, reduced high density (HDL-C), increased non-HDL-C, apolipoprotein B, LDL particle concentration, small, dense particles. increases CVD risk, at least partially due promotion adiposopathic, atherogenic profile. also worsens other cardiometabolic risk factors. patients interventions that reduce improve outcomes are generally associated improved levels. Given improvement LDL-C reduction overweight or early treat both (LDL-C and/or non-HDL-C) priorities reducing CVD.
Language: Английский
Citations
19
The Journal of Clinical Endocrinology & Metabolism, Journal Year: 2024, Volume and Issue: 109(11), P. 2709 - 2719
Published: July 23, 2024
Abstract The gut microbiota (GM), comprising trillions of microorganisms in the gastrointestinal tract, is a key player development obesity and related metabolic disorders, such as type 2 diabetes (T2D), syndrome (MS), cardiovascular diseases. This mini-review delves into intricate roles mechanisms GM these conditions, offering insights potential therapeutic strategies targeting microbiota. review elucidates diversity human GM, highlighting its pivotal functions host physiology, including nutrient absorption, immune regulation, energy metabolism. Studies show that dysbiosis linked to increased extraction, altered pathways, inflammation, contributing obesity, MS, T2D. interplay between dietary habits composition explored, underscoring influence diet on microbial functions. Additionally, addresses impact common medications interventions like fecal transplantation composition. evidence so far advocates for further research delineate modulation mitigating diseases, emphasizing necessity clinical trials establish effective sustainable treatment protocols.
Language: Английский
Citations
17
Obesity Pillars, Journal Year: 2023, Volume and Issue: 5, P. 100056 - 100056
Published: Jan. 28, 2023
This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) is intended to provide clinicians an overview of type 2 diabetes mellitus (T2DM), obesity-related cardiometabolic risk factor.
Language: Английский
Citations
32
Obesity Pillars, Journal Year: 2022, Volume and Issue: 3, P. 100026 - 100026
Published: July 5, 2022
Language: Английский
Citations
35
Obesity Pillars, Journal Year: 2022, Volume and Issue: 3, P. 100034 - 100034
Published: Aug. 10, 2022
This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) is intended to provide clinicians an overview of 30 common obesity myths, misunderstandings, and/or oversimplifications. The scientific support for this CPS based upon published citations, clinical perspectives OMA authors, and peer review by the leadership. discusses oversimplifications, utilizing referenced publications such as integrative use other CPSs help explain applicable physiology/pathophysiology. on oversimplifications one a series designed assist in care patients with disease obesity. Knowledge underlying science may medicine clinician improve
Language: Английский
Citations
26
Obesity Pillars, Journal Year: 2023, Volume and Issue: 8, P. 100092 - 100092
Published: Oct. 19, 2023
This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) is intended to provide clinicians with an overview on obesity, thrombosis, venous disease, lymphatic and lipedema.
Language: Английский
Citations
13
Obesity Pillars, Journal Year: 2022, Volume and Issue: 3, P. 100027 - 100027
Published: July 8, 2022
This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) provides clinicians an overview of nonalcoholic fatty liver disease (NAFLD), potential progression to steatohepatitis (NASH), and their application obesity.The scientific information for this CPS is based upon published citations, clinical perspectives OMA authors, peer review by the leadership.Topics include prevalence NAFLD NASH, NASH among patients with obesity, as well definitions, diagnosis, imaging, pathophysiology, differential role high fructose corn syrup other simple sugars, treatment (e.g., nutrition, physical activity, medications).This regarding obesity one a series CPSs designed assist in care obesity. Patients are at increased risk NASH. may benefit when who manage understand etiology, optimal goal prevent
Language: Английский
Citations
19
Obesity Pillars, Journal Year: 2023, Volume and Issue: 7, P. 100070 - 100070
Published: May 18, 2023
Language: Английский
Citations
11
Molecular Biology Reports, Journal Year: 2025, Volume and Issue: 52(1)
Published: March 14, 2025
Language: Английский
Citations
0